(Press-News.org) Madrid, Spain, 12 June 2013: The launch of the European Rheumatology Research Foundation (ERRF) was today announced at EULAR 2013, the Annual Congress of the European League Against Rheumatism.
The European Rheumatology Research Foundation (ERRF) is an independent, non-profit body devoted to promoting research in rheumatic and musculoskeletal diseases (RMDs). The ERRF supports high-quality, peer-reviewed research by raising funds from commercial and non-commercial donors. The ERRF aims to support basic and applied research in order to reduce the burden of disease for individuals with RMDs.
Professor Josef Smolen, President of ERRF, commented that "the foundation aims to recognise research and innovation in the field of rheumatology, which is crucial for improving our understanding of the causes of and pathways to RMDs, as well as their prevention and management. By supporting basic and clinical research, the ERRF aims to improve the quality of life and socio-economic conditions of more than 120 million Europeans living with RMDs."
"Thanks to a donation from EULAR, this year we are in a position to call for research proposals in the field of osteoarthritis. As the most common joint disorder in the world, and a leading cause of pain, disability and loss of function in adults, more research is needed to meet this significant unmet patient need," concluded Professor Paul Emery, Chair of the Executive Committee of the ERRF.
Revised systemic sclerosis classification to improve diagnosis
Collaboration between EULAR and the American College of Rheumatology has resulted in the development of new classification criteria for systemic sclerosis (SSc), replacing the 1980s criteria developed by the American Rheumatism Association (ARA), to improve diagnosis in patients with early and mild forms of the disease.
The President of EULAR, Professor Maxime Dougados said "systemic sclerosis is a debilitating chronic disease associated with skin thickening and changes to blood vessels, particularly those supplying the fingers and toes. This hardening of the skin is caused by a build-up of scar tissue, which can also occur in internal organs causing significant damage. The complexity and severity of SSc is a growing burden on healthcare systems; using up-to-date recommendations to accurately diagnose patients will allow them to properly treated."
A prospective observational study of 321 patients with SSc demonstrated that sensitivity of the new EULAR-ACR classification criteria for the overall cohort was 67% compared to 51% for the old ARA criteria, allowing more individuals to be classified as definitive SSc patients.
Evaluation of recommendations for the role of nurses in chronic inflammatory arthritis
Other announcements today included a study evaluating the application and agreement of recent EULAR recommendations for the role of nurses in the management of chronic inflammatory arthritis (CIA). The recommendations were distributed and assessed via a survey of 3594 nurses, rheumatologists and patients from 23 countries. Agreement and application of the recommendations was ranked on a scale of 0-10 (0: none, 10: high).
Agreement with the recommendations scored highly: the mean level of agreement was highest among nurses (8.1-9.8) and lowest among rheumatologists (6.8-9.5). Application of the recommendations was lower: the level of application was highest among nurses (5.6-7.3) and lowest among patients (2.6-5.7).
Disagreement with the recommendations from rheumatologists reportedly stemmed from doubts about the expertise of the nurses, whereas patients' disagreement mostly came from not wanting to lose contact with their rheumatologist.
EULAR formulated ten recommendations, seven of which covered the contribution of nurses to care and management of CIA. Large variances for the role of nurses in the management of CIA exist specifically between countries and regions. These data provide valuable information to support strategies for further implementation of the recommendations and homogenisation of rheumatology nursing care.
###
NOTES TO EDITORS:
For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress Press Office in room A10:14 of the Congress Centre during EULAR 2013 or on:
Email: eularpressoffice@cohnwolfe.com
EULAR Press Office
Onsite tel: +44 (0) 20 7331 5364 / 5380 / 5318 / 2305
About EULAR
The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations of people with rheumatic diseases throughout Europe
In line with the European Union of Medical Specialists (UEMS), EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.
EULAR aims to promote, stimulate and support the research, prevention, treatment and rehabilitation of rheumatic diseases
With 45 scientific member societies, 36 People with Arthritis and Rheumatism in Europe (PARE) organisations and 11 health professionals associations, EULAR underscores the importance of combating rheumatic diseases not only through medical means, but also through patient care
EULAR 2013 is set to be the biggest rheumatology event in Europe with over 14,000 scientists, physicians, allied health professionals and related audiences in attendance from more than 110 countries. Over the course of the congress there will be more than 320 oral and 1,800 poster abstract presentations, and 750 lectures with 330 invited speakers
To find out more about the activities of EULAR, visit: http://www.eular.org
EULAR 2013 highlights
Launch of European Rheumatology Research Foundation, new classification criteria for systemic sclerosis and evaluation of recommendations for chronic inflammatory arthritis
2013-06-12
ELSE PRESS RELEASES FROM THIS DATE:
Significant improvements in psoriatic arthritis with ustekinumab
2013-06-12
Madrid, Spain, 12 June 2013: New PSUMMIT 2* data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).
Anti-TNF naïve and anti-TNF-experienced patients randomised to one of two ustekinumab doses (45mg or 90mg) demonstrated significant and sustained improvements in the signs and symptoms of PsA, with favourable safety profiles.
PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life ...
Patients use OTC NSAIDs even when they have a high risk of serious side effects
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint.
Of these high risk OTC NSAID users, over one-third had taken the medication for more than 7 days, and 3% had exceeded the maximum recommended daily dosage.
Patients were considered at high risk of a serious ADE from OTC ...
Brodalumab demonstrates significant clinical response in psoriatic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis (PsA).
PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life in patients, and increases risk of co-morbid cardiovascular and gastrointestinal diseases.2 Psoriasis occurs in 2-3% of the population, with PsA occurring in ...
'Fast track' approach to giant cell arteritis significantly reduces risk of blindness
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that rapid evaluation for Giant Cell Arteritis (GCA) by Color Doppler Ultrasound (CDUS) followed by immediate initiation of treatment (if required) significantly reduces permanent vision loss.
Of the patients evaluated by the ''fast track'' principle from March 2010 to December 2012, 11.1% had transient visual manifestations, and none went on to suffer from permanent visual loss.
GCA is a condition in which medium and large-size arteries, ...
CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).
Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels ...
Abatacept as effective as adalimumab in rheumatoid arthritis
2013-06-12
Madrid, Spain, 12 June 2013: Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).
AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-naïve patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial.
RA is a ...
Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis
2013-06-12
Madrid, Spain, 12 June 2013: New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. For patients who completed 52 weeks of the study, up to 65% achieved ACR20* response rates. Also, apremilast continued to be well tolerated with an acceptable longer-term safety profile.
Apremilast is a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4). It works as an anti-inflammatory ...
New method successfully scores joint damage in rheumatoid arthritis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.
The study validated the use of ARASHI to assess joint damage in RA, and clarified the pattern of progression of damage during two-year TNF-blocking therapies. In addition to concluding the success of the scoring method, the data also showed that hip and knee joints with pre-existing damage were predisposed to continue destruction, even during ...
RA patients define ideal online tool for physical activity
2013-06-12
Madrid, Spain, 12 June 2013: Results of the first study involving RA patients in the development of an internet-based physical activity intervention were presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism.
These data show that seven categories are crucial for the adoption and maintenance of PA: personal incentives, personal mastering, information adapted to the Rheumatoid Arthritis (RA) condition, peer support, professional coaching, physical environment and resources, and societal support/financial assistance.
RA is a chronic autoimmune ...
Swiss ball improves muscle strength and walking performance in ankylosing spondylitis
2013-06-12
Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates that progressive muscle strengthening using a Swiss ball is effective in improving muscle strength and walking performance in patients with Ankylosing Spondylitis (AS).
Patients randomised to the exercise programme showed statistically significant improvements in muscle strength with no worsening of disease activity; in addition these patients reported greater satisfaction with their treatment than those in the control group.
AS ...
LAST 30 PRESS RELEASES:
NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
Chimpanzee stem cells offer new insights into early embryonic development
This injected protein-like polymer helps tissues heal after a heart attack
FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology
In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity
Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects
A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions
AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate
Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative
Structure dictates effectiveness, safety in nanomedicine
Mission accomplished for the “T2T” Hong Kong Bauhinia Genome Project
Study identifies how malaria can lead to childhood cancer
An earth-abundant mineral for sustainable spintronics
What makes successful learners? How Minecraft can helps us understand social learning
Researchers create ‘super stem cells’, seeing potential for improved fertility treatment
Empathic comforting varies more within bonobo and chimpanzee species than between them
AACR 2025: Colon cancer risk reduction, predicting melanoma spread and new drug therapies among Ohio State findings
Landmark 20-year screening program drives down colorectal cancer cases, deaths
Can a baby’s DNA predict future disease? This study says it might
Gene mutations linked to worse outcomes in stomach cancer
Blood proteins can predict liver disease up to 16 years before symptoms
Study: New DNA-reading technology holds promise for rare disease research
Study: Antibiotic exposure before age two linked to childhood obesity
Study: Artificial intelligence more accurately identifies child abuse
Study: Opioid use disorder treatment improves pregnancy outcomes
Study: Education improves in-home gun safety
Study: Treatment ineffective for newborns with low oxygen or blood supply
Study: Children with chronic conditions at risk for severe RSV outcomes
Study: Telehealth in pediatric primary care supports judicious antibiotic prescribing
Animal energy usage made visible through video
[Press-News.org] EULAR 2013 highlightsLaunch of European Rheumatology Research Foundation, new classification criteria for systemic sclerosis and evaluation of recommendations for chronic inflammatory arthritis